Case Report
Open Access
Severe Thoracic Trauma in Hemophilia-A Patient
with an Inhibitor
S Benhamza1*, M Lazraq1, L Boujmai1, A Bensaid1, Y Miloudi and N EL Harrar1
120 August Hospital, 1953, Ibn Rochd UHC of Casablanca, Morocco
*Corresponding author: Dr. Benhamza Sabah, Intensive Care Unit, 20 August Hospital, 20370, Hospital District, Casablanca, Morocco, Email:
@
Received: June 19, 2019; Accepted: July 12, 2019; Published: July 17, 2019
Citation: Benhamza S, Lazraq M, Boujmai L, Bensaid A, et al. (2019) Severe Thoracic Trauma in Hemophilia-A Patient with an Inhibitor. J Emerg Crit Care Diagn Manag 2(1): 1-3.
Hemophilia is a congenital bleeding disorder caused by the
absence or deficiency of a coagulation factors. Treatment consists
of intravenous administration of the decreased Factor VIII in the
case of hemophilia A or factor IX if it is hemophilia B. The presence
of alloantibodies (inhibitors) can make these factors less effective.
The management of these patients becomes difficult especially
in the context of the emergency. Our clinical case illustrates the
difficulty of making therapeutic decisions in the face of this kind of
patient with a focus on therapeutic alternatives.
Keywords: Haemophilia; Inhibitor; Thoracic Trauma
Keywords: Haemophilia; Inhibitor; Thoracic Trauma
Hemophilia A is a congenital bleeding disorder characterized
by a deficiency of factor VIII, and in whom infusion of the deficient
factor has considerably reduced the risk of hemorrhage linked
to this pathology. Nevertheless, the presence of an inhibitormay
limits the effectiveness of factor infusion. Inhibitors are a major
complication the treatment of haemophilia. The cumulative
incidence in cases of severe haemophilia A is reported to be 20
to 30% [1]. The management of these patients in the context
of trauma requires a different strategy from other cases of
hemophilia because of the high risk of bleeding and the potential
for factor VIII ineffectiveness. We report the case of a young
patient with major hemophilia A with an inhibitor, who was a
victim of severe thoracic trauma and for whom conservative
medical treatment was successfully employed.
We report the case of a 19 years old patient with severe
hemophilia A; with frequent on-demand use of factor VIII
following minor trauma. The patient fell from a height estimated
at one meterlanding on his right side. He presented to the
emergency department with bruising of the right flank with loss of
consciousness, and was hemodynamically and respiratory stable.
He was immediately infused with factor VIII, and then an injury
assessment was performed. The brain scan was normal, and the
abdominal CT scan revealed a 15-mm right peritoneal hematoma
with psoas hematoma and moderate peritoneal effusion. The
patient was hospitalized in the hematology department where he
continued to receive factor VIII, the hemoglobin was 5.2 g / dl
transfused with two red blood cells (CG) with a control at 7.2 g /
dl and an activated partial thromboplastin time (TCA) elongated
to 100 sec after receiving factor VIII. A search for inhibitor
was positive. The day after his trauma, the patient presented
respiratory distress for which he was admitted to intensive care.
At admission, the patient was agitated, tachypneic, cyanotic, had
signs of respiratory control with ringing rales, tachycardia at
135 beats / min, and pulse oxygen saturation (SPO2) was 60%
under FIO2 at 100%.A chest X-ray performed on the patient’s bed
showed opacity of the right lung suggesting a pleural effusion
(Figure 1), the pulmonary ultrasound showed a moderate right
effusion with bilateral condensation. After stabilization of noninvasively
ventilated (NIV) respiratory status and injection of
recombinant factor VII (rFVIIa), a thoraco-abdominal CT scan
was performed showing diffuse bilateral foci of predominance
on the left with moderate effusion and stationary images at the
abdominal level (Figures 2 and 3). After discussion we decided
not to drain this patient and opt for non invasive treatment. The
progress under NIV, rFVIIa factor, corticotherapy, diuretics was
satisfactory with regression of the effusion, radiography (Figure
4) and control pulmonary ultrasound, which became minimal
at the fourth day with aeration of the two lung fields. Patient
transferred after 7days of hospitalization.
Figure 1:Chest x-ray shows right pleural effusion
Figure 2:Thoracic CT scan showing bilateral pleural effusion with pulmonary
consolidation
Figure 3:Abdominal CT scan showing right peritoneal hematoma with
psosas hematoma
Figure 4:Chest x-ray showing good outcome without drainage
In thoracic traumas, thoracic drainage is indicated when
faced with any fluid or air effusion responsible for a respiratory
and / or hemodynamic (G1 +) failure, as well as in the face of any
haemothorax evaluated at more than 500 ml on the ultrasound
and / or the CT (G2 +) [2]. However, no recommendation is made
when dealing with patients with haemophilia whereas this area
is considered as a criterion for severity of thoracic trauma [2].
For any hemophilic patient, the principle is to administer factor
VIII immediately after admission to the emergency department
in order to restore normal hemostasis before considering other
procedures. However, frequent infusion of factor risks the
development an inhibitor which makes the substitution factor
ineffective and requires the use of another treatment [3]. At first
we should ensure an effective treatment of bleeding syndrome
[4], and then ensure the suppression of the immune response.
Screening for anti-VIII antibody should be done in any hemophilic
patient who has been taking on-demand factor therapy at times
and at frequencies that depend on the severity of the hemophilia.
For treatment of hemorrhagic syndrome [3-5], it depends on the inhibitor titer: Low responders, defined by an antibody titer of less than 5 Bethesda units, can be treated with large amounts of factor VIII at a single dose. whereas strong responders: a titer of antibodies greater than 5 Bethesda units are treated by agents bypassing the inhibitor, two molecules can be used which are: the recombinant activated factor VII (rFVIIa at a dose of 90-120 μg / kg every 2-4 hours) and plasma prothrombin-activated factor concentrate (FEIBA® dose of 50-100 U / kg every 8-12 hours) . Regarding the immunomodulatory treatment, it must be as early as possible in order to reduce the time of presence of the inhibitor and therefore the duration of exposure to bleeding risk. It combines oral corticosteroids (1 mg / kg / day) with oral cyclophosphamide (1 to 2 mg / kg / day) [1].
In our case, the patient had received factor VIII several times and has a major deficiency, which implies regular screening of inhibitor in order to avoid unjustified intake of factor VIII, especially in the context of the emergency. In our patient, although thoracic drainage was indicated according to the recommendations, we opted for a wait-and-see attitude with close ultrasound monitoring in view of the high risk of bleeding and especially to the clinical improvement under symptomatic and haemostatic treatment with rFVIIa.
The favorable outcome we describe gives food for thought to the indications of drainage in this kind of patients.
For treatment of hemorrhagic syndrome [3-5], it depends on the inhibitor titer: Low responders, defined by an antibody titer of less than 5 Bethesda units, can be treated with large amounts of factor VIII at a single dose. whereas strong responders: a titer of antibodies greater than 5 Bethesda units are treated by agents bypassing the inhibitor, two molecules can be used which are: the recombinant activated factor VII (rFVIIa at a dose of 90-120 μg / kg every 2-4 hours) and plasma prothrombin-activated factor concentrate (FEIBA® dose of 50-100 U / kg every 8-12 hours) . Regarding the immunomodulatory treatment, it must be as early as possible in order to reduce the time of presence of the inhibitor and therefore the duration of exposure to bleeding risk. It combines oral corticosteroids (1 mg / kg / day) with oral cyclophosphamide (1 to 2 mg / kg / day) [1].
In our case, the patient had received factor VIII several times and has a major deficiency, which implies regular screening of inhibitor in order to avoid unjustified intake of factor VIII, especially in the context of the emergency. In our patient, although thoracic drainage was indicated according to the recommendations, we opted for a wait-and-see attitude with close ultrasound monitoring in view of the high risk of bleeding and especially to the clinical improvement under symptomatic and haemostatic treatment with rFVIIa.
The favorable outcome we describe gives food for thought to the indications of drainage in this kind of patients.
For successful outcome, it seems necessary to make joint
recommendations between hematologists and resuscitators
as well as thoracic surgeons taking into account its particular
situations.
We thank the Hemato-Oncology Service of the Hospital
August 20, UHC Ibn Rochd Casablanca.
ReferencesTop
- Guidelines for managementof haemophilia in australia. Australian haemophilia centre director’s organization. 2016.
- Chest trauma: Strategy of care in the first 48 hours. Anesth Reanim. 2015;1(3):272–287.
- Witmer C, Young G. Factor VIII inhibitors in hemophilia A: rationale and latest evidence. Ther Adv Hematol. 2013;4(1):59-72. doi: 10.1177/2040620712464509
- Huth-Kuhne A, Baudo F, Collins P, Ingerslev J, Kessler CM, Levesque H, et al. International recommendations on the diagnosis and treatment of patients with acquired hemophilia A. Haematologica. 2009;94(4):566-575. doi: 10.3324/haematol.2008.001743
- Kempton CL, White GC II. How we treat à hemophilia A patient with à factor VIII inhibitor. Blood. 2009;113(1):11-17. doi: 10.1182/blood-2008-06-160432





